This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcasts3D Body AtlasLet’s connectLet's connectContact usSign up

Menu

Close

OverviewStarting Strong in 1LAbout LORVIQUA®Study Design1L study design2L+ study designEfficacy1L overall efficacy1L CNS efficacy1L 5-Year overall efficacy1L 5-Year CNS efficacy2L+ efficacySafetyPooled Safety: all lines1L safety2L+ safetyDosing & Therapy ManagementOnce-daily dosingARs of clinical interestTherapy managementResourcesMaterialsVideos
Prescribing Information 
A once-daily oral treatment with flexible dosing to manage adverse reactions1

For special warnings and precautions for use, please see the LORVIQUA® SmPC.1

  • LORVIQUA® should be swallowed whole, with or without food—never chewed, crushed, or split1

  • LORVIQUA® is contraindicated in patients taking strong CYP3A4/5 inducers concomitantly* and in those with hypersensitivity to LORVIQUA® or any of the excipients of LORVIQUA®1

  • For patients taking LORVIQUA®, alternative concomitant medicinal products with less potential to inhibit CYP3A4/5 should be considered1,*

  • Patients should avoid grapefruit products while taking LORVIQUA®1
  • Treatment with LORVIQUA® should be continued until disease progression or unacceptable toxicity1

 

Learn more about therapy management

*Please refer to the LORVIQUA® SmPC for recommendations regarding the use of CYP3A4/5 inducers and CYP3A4/5 inhibitors.AR=adverse reaction;  CNS=central nervous system; CYP3A4/5=cytochrome P450 3A4/5; SmPC=Summary of Product Characteristics.ReferencesReference:

Pfizer. LORVIQUA® (lorlatinib) Summary of Product Characteristics. 

Dosing & Therapy Management
LORVIQUA® safety profile
 Review the safety Loading
LORVIQUA® efficacy
 Discover the data Loading
PP-LOR-IRL-0185 | JUL2025

Adverse events should be reported.

If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363 
or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie

Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.Registered in the Republic of Ireland No. 127002. Directors: M. Adamson (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.

 

Copyright © 2025 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0937. July 2025
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0901. July 2025

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0901. July 2025